| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aedbf07ecbfa28ee6f4ec0c6b131e1d8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2c19cff3db6c302a9def325349f1c57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_495c344a74b82be1561fc928779cd80d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba27b12b4054759380ed2283e5272bc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cb4a68afcc71a0579e3b7df1b8929c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dbb0f8be0d4a9e4adb7b12e51af9969 |
| publicationDate |
2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114344461-A |
| titleOfInvention |
CLEC12AxCD3 bispecific antibodies and methods for treating disease |
| abstract |
The present invention relates to CLEC12AxCD3 bispecific antibodies and methods for treating disease, in particular to CLEC12A positive cancer components and methods of treating individuals. In some embodiments, the method comprises treating an individual in need thereof with two or more administrations of a bispecific antibody that binds CDS and CLEC12A, wherein a first amount of the bispecific antibody is administered in a first administration and wherein the amount of the bispecific antibody in each subsequent administration is higher than the amount of the bispecific antibody in the first administration. In some embodiments, a dosing regimen that provides CLEC 12A-positive cancer treatment at intervals and retains hematopoietic stem cell compartments allows for the recovery of normal CLEC 12A-positive hematopoietic cells. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |